Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms

abstract

  • Dose-dense sequential adjuvant chemotherapy with doxorubicin, paclitaxel, and cyclophosphamide (A-->T-->C) is feasible and promising. Several ongoing phase III trials are evaluating this approach.

publication date

  • January 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10458222

Additional Document Info

start page

  • 93

end page

  • 100

volume

  • 17

number

  • 1